Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Clearside Biomedical Inc. | Bel-sar (AU-011) - (CoMpass) | Indeterminate lesions (ILs) and choroidal melanoma (CM) | Phase 3 | Data Released | Intravitreal injection | Oncology |
| Clearside Biomedical Inc. | RGX-314 - (AAVIATE) | Wet AMD using suprachoroidal delivery | Phase 2 | Data Released | Intravitreal injection | Opthalmic |
| Clearside Biomedical Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | Phase 2 | Data Released | Suprachoroidal injection | Opthalmic |
| Clearside Biomedical Inc. | CLS-AX - (OASIS) | Wet age-related macular degeneration | Phase 2b | Type Meeting | Intravitreal injection | Opthalmic |
| Clearside Biomedical Inc. | CLS-AX - (ODYSSEY) | Neovascular age-related macular degeneration (wet AMD) | Phase 2b | Data Released | Intravitreal injection | Opthalmic |
| Clene Inc. | CNM-Au8 - (REPAIR-PD) | Parkinson's Disease | Phase 2 | Trial Completed | oral | Neurology |
| Clene Inc. | CNM-ZnAg | COVID-19 | Phase 2 | Trial Discontinued | oral | COVID-19 |
| Clene Inc. | CNM-Au8 - (VISIONARY-MS) | Multiple Sclerosis | Phase 2 | Trial Completed | Oral | Neurology |
